Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from David Risinger

The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.

Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

Investors Business Daily

Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News

Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use additive products.

Investors Business Daily

S&P, Dow Pharma Stocks Boomerang On Drug-Pricing Order That Is 'All Bark' And 'Little Bite'

Pharmaceutical stocks boomeranged Monday after Trump signed an executive order tying drug prices in the U.S. to international price tags.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks

Vertex stock skidded Tuesday on a series of first-quarter setbacks that included light sales, slow uptake for two drugs and a paused study.

Investors Business Daily

S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash

Pharma stocks tumbled Thursday after the Trump administration said the delay for reciprocal tariffs doesn't apply to sector-specific tariffs.

Investors Business Daily

Is This Dividend Stock a Buy After Better-Than-Expected Q4 Results?

Upcoming clinical trial results will give investors a much better look into Pfizer’s operational health.

Barchart

It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care

The Senate voted Thursday to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

Investors Business Daily

After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

Investors Business Daily

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga

AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback

AbbVie stock popped Friday after an analyst upgraded it on the remaining opportunity for its Cerevel takeover despite a huge misstep.

Investors Business Daily

Biotech Stocks Edge Higher. Could Trump 2.0 Mean More Innovation, Dealmaking?

Biotech stocks jumped early Wednesday on hopes for more innovation and dealmaking after Donald Trump clinched his second presidency.

Investors Business Daily

AnaptysBio Surges After Sanofi Takes A Stake In $100 Million Offering

AnaptysBio stock zoomed higher Wednesday after announcing a $100 million offering that includes participation from pharma giant Sanofi.

Investors Business Daily

Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results

Structure Therapeutics stock roses sharply Monday after the biotech company delivered "compelling" results for its weight-loss drug.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

IBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views

Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.

Investors Business Daily

The Bad News Heading Into AbbVie's First-Quarter Earnings Report

AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.

Investors Business Daily

Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?

Regeneron stock toppled Thursday after the DOJ filed a lawsuit saying the drugmaker fraudulently inflated the prices of its drug, Eylea.

Investors Business Daily

Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again

There's more than Eylea to like about Regeneron Pharmaceuticals right now, an analyst said Friday as REGN stock touched another record high.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Vertex Breaks Out To Record High As It Takes On Opioids In Pain Treatment

Vertex solidified its potential for an alternative to opioids in pain treatment, an analyst said Wednesday. VRTX stock broke out.

Investors Business Daily

Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning

Biogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started.

Investors Business Daily

Amgen Stock Surges To 10-Month High, Up 5% On An Unexpected Upgrade

Amgen stock snagged an upgrade Wednesday and surged to a 10-month high as one analyst examined the biotech behemoth's post-Horizon future.

Investors Business Daily

Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Price

Bristol Myers Squibb offered to buy Mirati Therapeutics for up to $5.8 billion, but MRTX stock tumbled on the lowball price.

Investors Business Daily

Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales

Biotech stock Roivant — founded by presidential candidate Vivek Ramaswamy — reported steep losses and lighter sales.

Investors Business Daily

Why Lilly's Obesity Treatment Update Sent Novo, Madrigal And Viking Shares Diving

Eli Lilly stock surged closer to a record high Tuesday after the company set a new bar in the industry for weight-loss medications.

Investors Business Daily

Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.

Lilly's Alzheimer's treatment could reach blockbuster status by 2025, an analyst said Monday. Eli Lilly stock is trading near a record high.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Trump Administration

823 stories

Investor Business Daily

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.